GEN Receives Ethical Approval to Launch Phase II Clinical Trial for SUL-238 Targeting Mitochondrial Dysfunction in Patients with Parkinson’s Disease

Author: GEN Ilac ve Saglik Urunleri A.S.

Posted Date: